title: Effect of alcohol consumption on liver stiffness measured by transient elastography.
abstract: OBJECTIVE
  To determine the evolution of transient elastography (TE) in patients with alcoholic liver disease according to alcohol cessation or continuation.
  
  
  METHODS
  We retrospectively selected in our local database all patients who had two TE between June 2005 and November 2010 with chronic alcohol excessive consumption and excluded those with associated cause of liver disease. TE was performed at least one week apart by senior operator. TE examinations with less than ten successful measures or with an interquartile range above 30% were excluded. We retrospectively reviewed file of all patients to include only patient followed up by trained addictologist and for which definite information on alcohol consumption was available. Concomitant biological parameters [aspartate amino transferase (AST), alanine amino transferase and gamma-glutamyl transpeptidase (GGT)] within 4 wk of initial and final TE were recorded. Putative fibrosis score according to initial and final TE were determined with available cut-off for alcoholic liver disease and hepatitis C. Initial and final putative fibrosis score were compared according to alcohol consumption during follow-up.
  
  
  RESULTS
  During the study period 572 patients had TE examination for alcoholic liver disease and 79 of them had at least two examinations. Thirty-seven patients met our criteria with a median follow-up of 32.5 wk. At the end of the study, 13 (35%) were abstinent, and 24 (65%) relapsers. Eight patients had liver biopsy during follow-up. TE decreased significantly during follow-up in 85% of abstinent patients [median (range): -4.9 (-6.1,-1.9)], leading to a modification of the putative fibrosis stage in 28%-71% of patient according to different cut-off value. In relapsers TE increased in 45% and decreased in 54% of patient. There was no statistical difference between initial and final TE in relapsers. In the overall population, using 22.6 kPa as cut-off for cirrhosis, 4 patients had cirrhosis at initial TE and 3 patients had cirrhosis at final TE. Using 19.5 kPa as cut-off for cirrhosis, 7 patients had cirrhosis at initial TE and 5 patients had cirrhosis at final TE. Using 12.5 kPa as cut-off for cirrhosis, 16 patients had cirrhosis at initial TE and 15 patients had cirrhosis at final TE. Evolution of biological data was in accordance with the relapse or abstinent status: abstinence ratio (duration of abstinence/duration follow-up) was correlated with AST ratio (r = -0.465, P = 0.007) and GGT ratio (r = -0.662, P < 0.0001). GGT was correlated with initial (r = 0.488, P = 0.002) and final TE (r = 0.49, P < 0.005). Final TE was correlated with AST (r = 0.362, P < 0.05). Correlation between TE ratio and AST ratio (r = 0.44, P = 0.01) revealed that TE varied proportionally to AST for all patients irrespective of their alcohol status. The same relationship was observed between TE ratio and GGT ratio (r = 0.65, P < 0.0001). Evolution of TE was significantly correlated with the ratio of time of abstinence to observation time (r = -0.387, P = 0.016) and the evolution of liver enzymes.
  
  
  CONCLUSIONS
  TE significantly decreased with abstinence. Results of TE in alcoholic liver disease cannot be interpreted without taking into account alcohol consumption and liver enzymes.
authors: Hepatology and Addictology Department, University Hospital Pontchaillou, F35000 Rennes, France. edouard.bardou-jacquet@chu-rennes.fr
authors: Edouard
authors: E
authors: Bardou-Jacquet
authors: Ludivine
authors: L
authors: Legros
authors: Draman
authors: D
authors: Soro
authors: Marianne
authors: M
authors: Latournerie
authors: Anne
authors: A
authors: Guillygomarc'h
authors: Caroline
authors: C
authors: Le Lan
authors: Pierre
authors: P
authors: Brissot
authors: Dominique
authors: D
authors: Guyader
authors: Romain
authors: R
authors: Moirand
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D064829:Alcohol Abstinence; D000428:Alcohol Drinking / Q000009:adverse effects* / Q000517:prevention & control; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D016009:Chi-Square Distribution; D018450:Disease Progression; D004548:Elasticity; D054459:Elasticity Imaging Techniques; D005260:Female; D006801:Humans; D008099:Liver / Q000201:enzymology / Q000473:pathology*; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D015415:Biomarkers; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
keywords: Alcohol; Cirrhosis; Fibrosis; Liver biopsy; Liver stiffness; Transient elastography
references: J Hepatol. 1986;2(2):165-73
references: 3958472
references: World J Gastroenterol. 2010 Feb 28;16(8):966-72
references: 20180235
references: Hepatology. 2005 Jan;41(1):48-54
references: 15690481
references: Hepatology. 1996 Aug;24(2):289-93
references: 8690394
references: J Viral Hepat. 2009 May;16(5):300-14
references: 19254351
references: Aliment Pharmacol Ther. 2011 Aug;34(3):353-62
references: 21631559
references: Liver Int. 2009 Feb;29(2):242-7
references: 18637064
references: Am J Health Syst Pharm. 2007 Mar 1;64(5 Suppl 3):S5-11
references: 17322182
references: Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1331-4
references: 15618841
references: J Hepatol. 2011 Aug;55(2):245-64
references: 21371579
references: Alcohol Alcohol. 2008 Jul-Aug;43(4):393-7
references: 18385413
references: Hepatology. 2010 Feb;51(2):454-62
references: 20101745
references: N Engl J Med. 2001 Feb 15;344(7):495-500
references: 11172192
references: Ann Hepatol. 2012 Mar-Apr;11(2):172-8
references: 22345333
references: Biol Chem. 2006 Apr;387(4):349-60
references: 16606331
references: J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S2-8
references: 18336658
references: Hepatology. 2006 Dec;44(6):1511-7
references: 17133503
references: Aliment Pharmacol Ther. 2009 Sep 15;30(6):557-76
references: 19519733
references: Gut. 2007 Jul;56(7):968-73
references: 17255218
references: Alcohol Clin Exp Res. 2011 Mar;35(3):566-70
references: 21143253
references: Gut. 2006 Mar;55(3):403-8
references: 16020491
references: J Hepatol. 2008 Dec;49(6):1062-8
references: 18930329
references: J Viral Hepat. 2007 May;14(5):360-9
references: 17439526
references: Hepatology. 2007 Sep;46(3):922-38
references: 17879356
references: Aliment Pharmacol Ther. 2008 Mar 1;27(5):441-7
references: 18081731
references: J Hepatol. 2012 Apr;56(4):908-43
references: 22424438
references: Gut. 2010 Jul;59(7):861-6
references: 20581229
references: Hepatology. 2006 May;43(5):1118-24
references: 16628644
references: Hepatology. 1999 Dec;30(6):1529-30
references: 10610352
references: Am J Gastroenterol. 2002 Feb;97(2):491-2
references: 11866299
references: J Gastrointestin Liver Dis. 2008 Dec;17(4):395-9
references: 19104699
references: Hepatology. 2008 Feb;47(2):592-5
references: 18098325
references: Liver Int. 2009 Jan;29 Suppl 1:19-22
references: 19207962
references: Gastroenterology. 2011 Jun;140(7):1970-9, 1979.e1-3
references: 21376047
references: Aliment Pharmacol Ther. 2008 Nov 15;28(10):1188-98
references: 18705692
references: Aliment Pharmacol Ther. 2006 Aug 1;24(3):513-8
references: 16886917